Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project

Vaccine

Volumn 34, Issue 48, 2016, Pages 5845-5854

  Liu, Heng ^a   Frijlink, Henderik W ^a   Huckriede, Anke ^b   van Doorn, Eva ^a   Schmidt, Ed ^a   Leroy, Odile ^c   Rimmelzwaan, Guus ^d   McCullough, Keneth ^e   Whelan, Mike ^f   Hak, Eelko ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c European Vaccine Initiative   (Germany)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (Switzerland)

^f IQUR LTD   (United Kingdom)

Author keywords

Broadly protective; Correlates of protection; EU consortia; Influenza; Vaccines

Indexed keywords

INFLUENZA VACCINE;

DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; EUROPE; HUMAN; IMMUNOGENICITY; INFLUENZA VACCINATION; PRIORITY JOURNAL; REVIEW; SEASONAL INFLUENZA; CHEMISTRY; ECONOMICS; EUROPEAN UNION; FINANCIAL MANAGEMENT; IMMUNOLOGY; INFLUENZA; MEDICAL RESEARCH; PANDEMIC;

BIOMEDICAL RESEARCH; EUROPEAN UNION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; RESEARCH SUPPORT AS TOPIC;

EID: 84994010401     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.10.040     Document Type: Review

References (76)

1. [1] World Health Organization [Internet]. Influenza (seasonal) fact sheet. Available from: < http://www.who.int/mediacentre/factsheets/fs211/en/> [updated 2016; cited 2016 Mar 22].
2. [2] Centers for Disease Control and Prevention [Internet]. Pink book-influenza. Available from: < http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/flu.pdf> [updated 2015 Sep 21; cited 2016 Mar 22].
3. [3] Marill, M.C., After flu vaccine mismatch, calls for delayed selection intensify. Nat Med 21:4 (2015), 297–298.
4. [4] European Center for Disease Prevention and Control [Internet]. Summarizing the 2014–2015 influenza season in Europe. Available from: < http://ecdc.europa.eu/en/press/news/_layouts/forms/News_DispForm.aspx?ID=1231&List=8db7286c-fe2d-476c-9133-18ff4cb1b568> [updated 2016; cited 2016 Mar 22].
5. [5] Chambers, B.S., Parkhouse, K., Ross, T.M., Alby, K., Hensley, S.E., Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014–2015 influenza season. Cell Rep 12:1 (2015), 1–6.
6. [6] Molbak, K., Espenhain, L., Nielsen, J., Tersago, K., Bossuyt, N., Denissov, G., et al. Excess mortality among the elderly in European countries. Eurosurveill, 20(11), 2015 pii: 21065. PubMed PMID: 25811643.
7. [7] Skowronski, D.M., Janjua, N.Z., Serres, G.D., Sabaiduc, S., Eshaghi, A., Dickinson, J.A., et al. Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not entigenic frift in circulating viruses. PLoS ONE, 9(3), 2014, e92153.
8. [8] Centers for Disease Control and Prevention [Internet]. The 2009 H1N1 pandemic: summary highlights, April 2009–April 2010. Available from: < http://www.cdc.gov/h1n1flu/cdcresponse.htm> [updated 2010 Aug 3; cited 2016 Mar 22].
9. [9] President's Council of Advisors on Science and Technology[Internet]. Report to the president on reengineering the influenza vaccine production enterprise to meet the challenges of pandemic influenza. Available from: < https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST-Influenza-Vaccinology-Report.pdf> 2010 [cited 2016 Mar 22].
10. [10] Work Programme 2013 [Internet]. Available from: < http://ec.europa.eu/research/participants/data/ref/fp7/192012/a-wp-201303_en.pdf> 2013 [cited 2016 Aug 31].
11. [11] Cox, N.J., Hickling, J., Jones, R., Rimmelzwaan, G.F., Lambert, L.C., Boslego, J., et al. Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5–7 May 2014. Vaccine 33:48 (2015), 6503–6510.
12. [12] World Health Organization [Internet]. Eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses. Available from: < http://www.who.int/immunization/research/meetings_workshops/8th_influenza_vaccine_chicago2016/en/> [updated 2016; cited 2016 Aug 31].
13. [13] European Commission [Internet]. Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure. Available from: < http://cordis.europa.eu/project/rcn/110279_en.html> [updated 2015 Mar 11; cited 2016 Mar 22].
14. [14] EDUFLUVAC consortium [Internet]. Educate the immune system to recognise common influenza epitope. Available from: < http://www.edufluvac.eu/> [updated 2016; cited 2016 Mar 22].
15. [15] Kusi, K.A., Faber, B.W., Thomas, A.W., Remarque, E.J., Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS ONE, 4(12), 2009, e8110.
16. [16] Schwartzman, L.M., Cathcart, A.L., Pujanauski, L.M., Qi, L., Kash, J.C., Taubenberger, J.K., An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of influenza A virus. MBio, 6(4), 2015 e01044-15.
17. [17] European Commission [Internet]. InFLUenza virus UNIVersal VACcine development program. Available from: < http://cordis.europa.eu/project/rcn/109606_en.html> [updated 2015 Oct 12; cited 2016 Mar 22].
18. [18] FLUNIVAC consortium [Internet]. FLUNIVAC. Available from: < http://flunivac.eu/> [updated 2016; cited 2016 Mar 22].
19. [19] Altenburg, A.F., Kreijtz, J.H., de Vries, R.D., Song, F., Fux, R., Rimmelzwaan, G.F., et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6:7 (2014), 2735–2761.
20. [20] Brewoo, J.N., Powell, T.D., Jones, J.C., Gundlach, N.A., Young, G.R., Chu, H., et al. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia ankara (MVA) vectored vaccine in mice. Vaccine 31:14 (2013), 1848–1855.
21. [21] Antrobus, R.D., Lillie, P.J., Berthoud, T.K., Spencer, A.J., McLaren, J.E., Ladell, K., et al. A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS ONE, 7(10), 2012, e48322.
22. [22] Kreijtz, J.H., Goeijenbier, M., Moesker, F.M., van den Dries, L., Goeijenbier, S., De Gruyter, H.L., et al. Safety and immunogenicity of a modified-vaccinia-virus-ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. Lancet Infect Dis 14:12 (2014), 1196–1207.
23. [23] Bavarian Nordic [Internet]. IMVAMUNE. Available from: < http://www.bavarian-nordic.com/about/company-overview.aspx>.
24. [24] European Commission [Internet]. A “Universal” influenza vaccine through synthetic, dendritic cell-targeted, self-replicating RNA vaccine. Available from: < http://cordis.europa.eu/project/rcn/109454_en.html> [updated 2015 Jun 29; cited 2016 Mar 22].
25. [25] UNIVAX consortium [Internet]. UNIVAX. Available from: < http://www.univax-fp7.eu/index.php?id=1292> [cited 2016 Mar 22].
26. [26] Atkins, G.J., Fleeton, M.N., Sheahan, B.J., Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med, 10, 2008, e33.
27. [27] Khromykh, A.A., Replicon-based vectors of positive strand RNA viruses. Curr Opin Mol Ther 2:5 (2000), 555–569.
28. [28] McCullough, K.C., Bassi, I., Demoulins, T., Thomann-Harwood, L.J., Ruggli, N., Functional RNA delivery targeted to dendritic cells by synthetic nanoparticles. Ther Deliv 3:9 (2012), 1077–1099.
29. [29] Tratschin JD, Ruggli N, McCullough KC. Pestivirus replicons providing an RNA-based viral vector system. United States Patent US 20110189224 A1; 2008 Jun 4.
30. [30] McCullough, K.C., Milona, P., Thomann-Harwood, L., Démoulins, T., Englezou, P., Suter, R., et al. Self-amplifying replicon RNA vaccine delivery to dendritic cells by synthetic nanoparticles. Vaccines (Basel) 2:4 (2014), 735–754.
31. [31] Milona P, Bovin N, McCullough KC. Enhanced translational DC targeting: wide carbohydrate ligand screening on human and porcine dendritic cells; 2016 [submitted for publication].
32. [32] Ebensen, T., Libanova, R., Schulze, K., Yevsa, T., Morr, M., Guzman, C.A., Bis-(3′,5′)-cyclic dimeric adenosine monophosphate: strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 29:32 (2011), 5210–5220.
33. [33] Libanova, R., Ebensen, T., Schulze, K., Bruhn, D., Nörder, M., Yevsa, T., et al. The member of the cyclic di-nucleotide family bis-(3′,5′)-cyclic dimeric inosine monophosphate exerts potent activity as mucosal adjuvant. Vaccine 28:10 (2010), 2249–2258.
34. [34] Ebensen, T., Guzman, C.A., Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design. Adv Exp Med Biol 655 (2009), 171–188.
35. [35] Madhun, A.S., Haaheim, L.R., Nostbakken, J.K., Ebensen, T., Chichester, J., Yusibov, V., et al. Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine 29:31 (2011), 4973–4982.
36. [36] Svindland, S.C., Pedersen, G.K., Pathirana, R.D., Bredholt, G., Nøstbakken, J.K., Jul-Larsen, Å., et al. A study of Chitosan and c-di-GMP as mucosal adjuvants for intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses 7:6 (2013), 1181–1193.
37. [37] Demoulins, T., Milona, P., Englezou, P.C., Ebensen, T., Schulze, K., Suter, R., et al. Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines. Nanomedicine, 2015 pii: S1549-9634. PubMed PMID: 26592962.
38. [38] McCullough, K.C., Bassi, I., Milona, P., Suter, R., Thomann-Harwood, L., Englezou, P., et al. Self-replicating replicon-RNA delivery to dendritic cells by chitosan-nanoparticles for translation in vitro and in vivo. Mol Ther Nucl Acids, 3, 2014, e173.
39. [39] Svindland, S.C., Jul-Larsen, A., Pathirana, R., Andersen, S., Madhun, A., Montomoli, E., et al. The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine. Influenza Other Respir Viruses 6:2 (2012), 90–100.
40. [40] Cox, R.J., Pedersen, G., Madhun, A.S., Svindland, S., Sævik, M., Breakwell, L., et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 29:45 (2011), 8049–8059.
41. [41] European Commission [Internet]. Development of a universal influenza vaccine based on tandem core technology. Available from: < http://cordis.europa.eu/project/rcn/109344_en.html> [updated 2015 Mar 11; cited 2016 Mar 22].
42. [42] FLUTCORE consortium [Internet]. FLUTCORE. Available from: < http://www.flutcore.eu/> [updated 2016; cited 2016 Mar 22].
43. [43] Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W.M., Fiers, W., A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:10 (1999), 1157–1163.
44. [44] Nabel, G.J., Fauci, A.S., Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med 16:12 (2010), 1389–1391.
45. [45] Peyret, H., Gehin, A., Thuenemann, E.C., Blond, D., El Turabi, A., Beales, L., et al. Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins. PLoS ONE, 10(4), 2015, e0120751.
46. [46] European Commission [Internet]. Universal influenza vaccines secured. Available from: < http://cordis.europa.eu/project/rcn/110139_en.html> [updated 2015 Mar 11; cited 2016 Mar 22].
47. [47] UNISEC consortium [Internet]. Universal influenza vaccines secured. Available from: < http://www.unisecconsortium.eu/> [updated 2016 Oct 16; cited 2016 Mar 22].
48. [48] Pleguezuelos, O., Robinson, S., Stoloff, G.A., Caparros-Wanderley, W., Synthetic influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled phase I trial. Vaccine 30:31 (2012), 4655–4660.
49. [49] Pleguezuelos, O., Robinson, S., Fernandez, A., Stoloff, G.A., Mann, A., Gilbert, A., et al. A synthetic influenza virus vaccine induces a cellular immune response that correlates with reduction in symptomatology and virus shedding in a randomized phase Ib live-virus challenge in humans. Clin Vaccine Immunol 22:7 (2015), 828–835.
50. [50] Atsmon, J., Kate-Ilovitz, E., Shaikevich, D., Singer, Y., Volokhov, I., Haim, K.Y., et al. Safety and immunogenicity of multimeric-001 – a novel universal influenza vaccine. J Clin Immunol 32:3 (2012), 595–603.
51. [51] Atsmon, J., Caraco, Y., Ziv-Sefer, S., Shaikevich, D., Abramov, E., Volokhov, I., et al. Priming by a novel universal influenza vaccine (multimeric-001)-a gateway for improving immune response in the elderly population. Vaccine 32:44 (2014), 5816–5823.
52. [52] European Medicines Agency. Explanatory note on the withdrawal of the note for guidance on harmonisation of requirements for influenza vaccines and of the core SmPC/PL for inactivated seasonal influenza vaccines, EMA/CHMP/VWP/40560/2014; 2014.
53. [53] Wijnans, L., Voordouw, B., A review of the changes to the licensing of influenza vaccines in Europe. Influenza Other Respir Viruses 10:1 (2016), 2–8.
54. [54] Impagliazzo, A., Milder, F., Kuipers, H., Wagner, M.V., Zhu, X., Hoffman, R.M., et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349:6254 (2015), 1301–1306.
55. [55] Yassine, H.M., Boyington, J.C., McTamney, P.M., Wei, C.J., Kanekiyo, M., Kong, W.P., et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med 21:9 (2015), 1065–1070.
56. [56] FLUCOP consortium [Internet]. Standardisation and development of assays for assessment of influenza vaccine correlates of protection. Available from: < http://www.flucop.eu/> [updated 2016; cited 2016 Mar 22].
57. [57] Janetzki, S., Hoos, A., Melief, C.J., Odunsi, K., Romero, P., Britten, C.M., Structured reporting of T cell assay results. Cancer Immun, 13, 2013, 13.
58. [58] Jayasundara, K., Soobiah, C., Thommes, E., Tricco, A.C., Chit, A., Natural attack rate of influenza in unvaccinated children and adults: a meta-regression analysis. BMC Infect Dis, 14, 2014, 670.
59. [59] Rappuoli, R., The challenge of developing universal vaccines. F1000 Med Rep, 3, 2011, 16.
60. [60] Alving, C.R., Peachman, K.K., Rao, M., Reed, S.G., Adjuvants for human vaccines. Curr Opin Immunol 24:3 (2012), 310–315.
61. [61] van Doorn, E., Liu, H., Huckriede, A., Hak, E., Safety and tolerability evaluation of the use of Montanide ISA™ 51 as vaccine adjuvant: a systematic review. Hum Vaccin Immunother 12:1 (2016), 159–169.
62. [62] Liu, H., Patil, H.P., de Vries-Idema, J., Wilschut, J., Huckriede, A., Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100. PLoS ONE, 7(12), 2012, e52135.
63. [63] Waldman, R.H., Mann, J.J., Kasel, J.A., Influenza virus neutralizing antibody in human respiratory secretions. J Immunol 100:1 (1968), 80–85.
64. [64] Waldman, R.H., Wood, S.H., Torres, E.J., Small, P.A. Jr., Influenza antibody response following aerosal administration of inactivated virus. Am J Epidemiol 91:6 (1970), 574–585.
65. [65] Waldman, R.H., Coggins, W.J., Influenza immunization: field trial on a university campus. J Infect Dis 126:3 (1972), 242–248.
66. [66] Tonnis, W.F., Lexmond, A.J., Frijlink, H.W., de Boer, A.H., Hinrichs, W.L., Devices and formulations for pulmonary vaccination. Expert Opin Drug Deliv 10:10 (2013), 1383–1397.
67. [67] Amorij, J.P., Hinrichs, W.L., Frijlink, H.W., Wilschut, J.C., Huckriede, A., Needle-free influenza vaccination. Lancet Infect Dis 10:10 (2010), 699–711.
68. [68] Ball, R., Horne, D., Izurieta, H., Sutherland, A., Walderhaug, M., Hsu, H., Statistical, epidemiological, and risk-assessment approaches to evaluating safety of vaccines throughout the life cycle at the food and drug administration. Pediatrics 127:Suppl. 1 (2011), S31–S38.
69. [69] Khurana, S., Loving, C.L., Manischewitz, J., King, L.R., Gauger, P.C., Henningson, J., et al. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med, 5(200), 2013, 200ra114.
70. [70] Ahmed, S.S., Volkmuth, W., Duca, J., Corti, L., Pallaoro, M., Pezzicoli, A., et al. Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Sci Transl Med, 7(294), 2015, 294ra105.
71. [71] Krammer, F., Palese, P., Advances in the development of influenza virus vaccines. Nat Rev Drug Discov 14:3 (2015), 167–182.
72. [72] Wiersma, L.C., Rimmelzwaan, G.F., de Vries, R.D., Developing universal influenza vaccines: hitting the nail, not just on the head. Vaccines (Basel) 3:2 (2015), 239–262.
73. [73] Trombetta, C.M., Perini, D., Mather, S., Temperton, N., Montomoli, E., Overview of serological techniques for influenza vaccine evaluation: past, present and future. Vaccines (Basel) 2:4 (2014), 707–734.
74. [74] Jegaskanda, S., Job, E.R., Kramski, M., Laurie, K., Isitman, G., de Rose, R., et al. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 190:4 (2013), 1837–1848.
75. [75] Kristensen, A.B., Lay, W.N., Ana-Sosa-Batiz, F., Vanderven, H.A., Madhavi, V., Laurie, K.L., et al. Antibody responses with Fc-mediated functions after vaccination of HIV-infected subjects with trivalent influenza vaccine. J Virol 90:12 (2016), 5724–5734.
76. [76] Ana-Sosa-Batiz, F., Vanderven, H., Jegaskanda, S., Johnston, A., Rockman, S., Laurie, K., et al. Influenza-specific antibody-dependent phagocytosis. PLoS ONE, 11(4), 2016, e0154461.